Literature DB >> 20001223

Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'.

Hideki Araoka1, Masaru Baba, Shinsuke Takagi, Naofumi Matsuno, Kazuya Ishiwata, Nobuaki Nakano, Masanori Tsuji, Hisashi Yamamoto, Sachiko Seo, Yuki Asano-Mori, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shuichi Taniguchi, Akiko Yoneyama.   

Abstract

Metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa) is a cause of life-threatening infections. With parenteral colistin not available in Japan, we treated MDR P. aeruginosa sepsis with monobactam and aminoglycoside combination therapy, with screening using a 'break-point checkerboard plate'.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20001223     DOI: 10.3109/00365540903443157

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

1.  New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa.

Authors:  I Nakamura; T Yamaguchi; A Tsukimori; A Sato; S Fukushima; T Matsumoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-29       Impact factor: 3.267

Review 2.  Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.

Authors:  Tetsuya Matsumoto
Journal:  Clin Pharmacol       Date:  2014-09-26

Review 3.  Clinical Usefulness of Arbekacin.

Authors:  Jae Hoon Lee; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2016-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.